BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
BioCryst Pharmaceuticals missed estimated earnings by 8.11%, reporting an EPS of $-0.4 versus an estimate of $-0.37.
Revenue was up $30.86 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.1 which was followed by a 0.12% drop in the share price the next day.
Here's a look at BioCryst Pharmaceuticals's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.3 | -0.29 | -0.24 | -0.27 |
| EPS Actual | -0.4 | -0.33 | -0.24 | -0.36 |
| Revenue Estimate | 50.56M | 39.38M | 28.48M | 8.89M |
| Revenue Actual | 47.16M | 40.99M | 49.96M | 19.06M |
To track all earnings releases for BioCryst Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
